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Abstract
Background: The premature fusion of metopic sutures results in the clinical phenotype of trigonocephaly. An
association of this characteristic with the monosomy 9p syndrome is well established and the receptor-type protein
tyrosine phosphatase gene (PTPRD), located in the 9p24.1p23 region and encoding a major component of the
excitatory and inhibitory synaptic organization, is considered as a good candidate to be responsible for this form of
craniosynostosis. Moreover PTPRD is known to recruit multiple postsynaptic partners such as IL1RAPL1 which gene
alterations lead to non syndromic intellectual disability (ID).
Results: We describe a 30 month old boy with severe intellectual disability, trigonocephaly and dysmorphic facial
features such as a midface hypoplasia, a flat nose, a depressed nasal bridge, hypertelorism, a long philtrum and a
drooping mouth.
Microarray chromosomal analysis revealed the presence of a homozygous deletion involving the PTPRD gene,
located on chromosome 9p22.3. Reverse Transcription PCR (RT-PCR) amplifications all along the gene failed to
amplify the patient's cDNA in fibroblasts, indicating the presence of two null PTPRD alleles.
Synaptic PTPRD interacts with IL1RAPL1 which defects have been associated with intellectual disability (ID) and
autism spectrum disorder. The absence of the PTPRD transcript leads to a decrease in the expression of IL1RAPL1.
These results suggest the direct involvement of PTPRD in ID, which is consistent with the PTPRD -/- mice
phenotype.
Deletions of PTPRD have been previously suggested as a cause of trigonocephaly in patients with monosomy 9p
and genome-wide association study suggested variations in PTPRD are associated with hearing loss.
Conclusions: The deletion identified in the reported patient supports previous hypotheses on its function in ID and
hearing loss. However, its involvement in the occurrence of metopic synostosis is still to be discussed as more
investigation of patients with the 9p monosomy syndrome is required.
Keywords: Protein tyrosine phosphatase receptor delta, Intellectual disability, Hearing loss, Trigonocephaly,
Monosomy 9p
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Background
Craniosynostosis is a developmental anomaly charac-
terized by a premature closure of one or several cranial
sutures, leading to alterations in skull shape. Its inci-
dence is 1 in 2000 to 2500 births and can be either
isolated or associated with different other features.
Nonsyndromic craniosynostosis is a multifactorial con-
dition caused by genetic and environmental contribu-
tions; whereas syndromic craniosynostosis is associated
with one of more than 180 identified monogenic syn-
dromes with known inheritance patterns and dysmorphic
features [1–3].
Metopic suture synostosis, resulting in trigonocephaly,
has an estimated incidence of 1:15,000 live births [1, 4].
Little is known about its etiology and different theories
have been proposed. An association of trigonocephaly
with chromosomal abnormalities, more specifically with
monosomy 9p syndrome (OMIM 158170) is well estab-
lished and the receptor-type protein tyrosine phosphat-
ase gene (PTPRD), located in the 9p24.1p23 region, was
considered as a good candidate to be responsible for this
form of craniosynostosis [5, 6].
Here we present a male child with a homozygous
microdeletion of the PTPRD gene. Our results support a
direct involvement of this gene in intellectual disability
(ID), hearing loss, and trigonocephaly.
Case presentation
Ethical statement
This study was carried out with protocols approved by
the Institutional Review Board (IRB) on human experi-
mentation at the Saint Joseph University.
Case report
The patient is a 30 month old boy, the second child of
healthy consanguineous Lebanese parents. He was born
at term via Cesarean section after an uneventful preg-
nancy. At birth, he weighed 2000 g.
He was referred to our laboratory at the age of 19 months
because of delay in developmental and language milestones.
He couldn't bottom-shuffle nor utter meaningful words.
He had a head circumference of 41.2 cm (<< 3rd per-
centile). Clinical examination showed microcephaly, trigo-
nocephaly, scaphocephaly, midface hypoplasia, a flat nose,
a depressed nasal bridge, downslanting palpebral fissures,
hypertelorism, low set and large ears, a long philtrum, and
a drooping mouth (Fig. 1b).
Brain magnetic resonance imaging (MRI) demonstrated
a skull with a dolichocephalic pattern, a mild pachygyria
of occipitoparietal lobes, and a mild widening of the
frontal pericerebral subarachnoid space. The audiogram
showed a bilateral hearing impairment with a hearing
threshold at 40 dB.
Fig. 1 Clinical and genetic findings in the proband. a Representation of deleted regions within PTPRD. Black bars represent the deleted
segments whereas the green one represents the BAC clone CTD-L2154L8 used in FISH. b Photograph of the proband at 3 years 6 months. The
patient shows trigonocephaly, scaphocephaly, midface hypoplasia, a flat nose, a depressed nasal bridge, downslanting palpebral fissures, low set
and large ears, a long philtrum, and a drooping mouth c FISH analysis confirming the presence of intron 8 on chromosome 9p. Arrowheads in
red indicate a centromeric probe on chr9, and arrows in green indicate CTD-2154L8 mapping IVS8
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At the age of 3 years and 6 months, his head circum-
ference was 44 cm (<3rd percentile), his weight was
8000 g, and his height was 75 cm (< 3rd percentile).
Results
Molecular karyotyping showed two adjacent deletions
spanning the 9p24.1p23 region 46,XY.arr 9p24.1p23
(8,527,597-9,248,069)x0,9p23(9,316,105-9,491,477)x0. Inter-
estingly, these two interstitial homozygous deletions con-
tained breakpoints within the PTPRD gene. They remove
exon 9, a part of intron 9, and exons 10 to 15 of the gene
(NM_002839) (Fig. 1a). No reported copy number vari-
ants that span these deletions were found in the Database
of Genomic Variants (http://projects.tcag.ca/variation/).
Both deletions were confirmed using quantitative PCR
and were found to be heterozygous in the proband's con-
sanguineous parents and brother (Fig. 2). FISH analysis
confirmed the presence of the undeleted intronic se-
quence of PTPRD on chromosome 9, ruling out a putative
insertion or translocation of this sequence on another
chromosome (Fig. 1c).
We next performed expression analysis in order to as-
certain a potential causative role for PTPRD in the patient
phenotype. We found that the PTPRD transcript is highly
expressed in the brain. Several transcripts were found in
brain and in the heart, in addition to a high expression in
the testis, lung, retina, and colon. Conversely, PTPRD
transcripts were found at low levels in the liver, kidney,
and fibroblasts, and absent in lymphocytes (Fig. 3).
RT-PCR amplifications all along the PTPRD gene failed
to amplify the patient's cDNA in fibroblasts, indicating that
the deletions present in the patient are null alleles (Fig. 4a).
Finally, we studied the effect of the absence of PTPRD
on the expression of IL1RAPL1 in fibroblasts because
PTPRD and IL1RAPL1 interact and because mutations
in the later are a cause of intellectual deficiency. We
found that IL1RAPL1 transcripts are reduced by 92 % in
the patient fibroblasts with respect to controls (Fig. 4b).
Discussion
This study provides the first description of a PTPRD
homozygous deletion, found in a patient with ID,
growth retardation, hearing loss, trigonocephaly and
scaphocephaly.
PTPRD belongs to the protein tyrosine phosphatase
family, dephosphorylating phosphotyrosine, and playing
essential roles in the regulation of receptor tyrosine kin-
ase, growth, cell migration, and angiogenesis [7]. In par-
ticular, PTPRD plays an important role in excitatory and
inhibitory synaptic organization. It is highly expressed in
the brain and in scattered cortical neurons, presumptive
interneurons, and CA2 hippocampal pyramidal cells [8].
Mouse and human PTPRD are 90 % and 96 % identi-
cal in the amino acid sequence of their extracellular and
cytoplasmic regions respectively [9]. Knockout PTPRD
mice exhibit growth retardation, posture and motor de-
fects, early mortality due to reduced food intake, impaired
memory and learning of spatial tasks, and enhanced long-
term potentiation at hippocampal synapses, supporting
the involvement of the PTPRD protein in synaptic func-
tions [10, 11].
The complete absence of the PTPRD transcript in the
patient described here might affect the postsynaptic recruit-
ment of multiple postsynaptic partners such as IL1RAPL1.
In mice, these protein-protein interactions regulate the
excitatory and inhibitory synapses development [12].
Mutations in IL1RAPL1 cause non-syndromic X-linked
ID. A neuronal overexpression of IL1RAPL1, through the
trans-synaptic indispensable interaction with PTPRD,
not only enhances excitatory presynaptic inputs but also
increases dendritic spine formation and clustering of ex-
citatory postsynaptic proteins. This synaptogenic activity
is abrogated in cortical neurons from PTPRD-deficient
mice [12, 13].
The study of the effects of this deletion on the synaptic
PTPRD-IL1RAPL1 interaction in the patient was not
possible. However, we found a reduction of 92 % of
IL1RAPL1 in the patient's fibroblasts tissue, supporting
an involvement of the loss of PTPRD in the patient's ID.
Fig. 2 Dosage of PTPRD gene content using quantitative PCR. The
bars represent the relative quantification of each sample. a The
proband has zero copies of the first deletion within the PTPRD gene
(chr9:8,527,597-9,248,069) and b zero copies of the second deletion
touching this gene (chr9:9,316,105-9,491,477) whereas his parents and
brother have a single copy compared to controls. P: patient, F: father,
M: mother, B: brother, C1,C2, and C3: controls
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Hemizygous deletions involving PTPRD were described
in probands with ADHD or autism. Both cognitive disor-
ders are acknowledged to be a common comorbidity for
individuals with intellectual disability [14–16].
On the basis of these data, PTPRD was considered as
responsible for the ID observed in the patient. However,
its direct involvement in craniosynostosis has never been
reported to date.
Studies on patients with monosomy 9p proposed PTPRD
as a candidate gene for metopic synostosis (OMIM
158170). Affected individuals have moderate to severe
ID, developmental and psychomotor delay, midface hypo-
plasia, long philtrum, and trigonocephaly [17]. Several
authors reduced the minimal critical region responsible
for this syndrome to the PTPRD gene (Fig. 5) [6, 18].
The patient described here shows similar clinical fea-
tures to those with monosomy 9p, especially trigonoce-
phaly and ID. However, the existence of heterozygous
deletions in the healthy consanguineous parents, brother,
and in some 9p patients showing no trigonocephaly, sug-
gests two hypotheses. On one hand, a possible recessive
autosomic transmission mode for this characteristic,
which imposes the contribution of additional mutations
of PTPRD or regulatory elements or genes in the occur-
rence of trigonocephaly in the patient here described
and other probands; especially those with monosomy 9p
previously reported. On the other hand, this form of
metopic synostosis is frequently unrecognized or misdiag-
nosed during infancy of which possibly the 9p monosomy
patients or patient's family, as metopic ridging without
Fig. 3 Expression of PTPRD in different tissues. Expression of PTPRD (top panels) and GAPGH (bottom panels) in a 13 human tissues and b 12
regions of the human brain. Several transcripts were found in the brain and in the heart, in addition to a high expression in the brain, testis, lung,
retina, and colon. Conversely, PTPRD transcripts were found at low levels in the liver, kidney, and fibroblasts, and absent in lymphocytes
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synostosis is very common and is estimated to occur in
10–25 % of normal infants and young children [19].
In addition, some members of the PTPRD family of pro-
teins are considered as regulators of craniofacial morpho-
genesis. PTPRE is an example, recognized to be implicated
in the formation and differentiation of osteoblasts and
whose haploinsufficiency increases trabecular bone mass
due to cell-specific defects in osteoclast function in young
females [20]. As some family members may retain similar
function, further studies are recommended to confirm the
involvement of PTPRD in trigonocephaly.
Loss of PTPRD expression could also be responsible
for the patient's hearing loss. Indeed, a genome-wide
association study in European populations suggested an
association between hearing impairement and a variation
in PTPRD (rs10815873; NM_002839.3:c.4086 + 398C.A)
[21, 22]. PTPRD is expressed in the outer and inner hair
cells, in the stria vascularis, the spiral ganglion, vestibu-
lar hair cells, and supporting cells, and was therefore
considered a good candidate gene due to its expression
pattern and the fact that it belongs to a family of
proteins previously implicated in auditory function.
Conclusions
The wide contribution of this gene in the phenotype of
the patient supports many previous hypotheses on its
function in ID, hearing loss, and trigonocephaly. How-
ever, its involvement in the occurrence of metopic syn-
ostosis is still to be discussed as more investigation of
patients with the 9p monosomy syndrome is required.
Meanwhile, parents were advised of a recurrence risk of
25 % of having another affected baby.
Methods
Cytogenetic and molecular techniques
Chromosomal microarray analysis (CMA)
Chromosomal microarray analysis was performed on
genomic DNA isolated from peripheral blood lymphocytes
(Kit Nucleospin Blood L, Macherey-Nagel, Eurl, Hoerdt,
France) using an Affymetrix Cytogenetics Whole Genome
Fig. 4 RT-PCR amplifications along the PTPRD gene and expression of IL1RAPL1 in fibroblasts using Q-PCR. a RT-PCR amplifications indicate that
no PTPRD transcript is found in the patient (P) in comparison to the control (C). GAPDH is used as an amplification control b Absence of the
PTPRD transcript in the patient and a reduction of 92 % in the expression of IL1RAPL1 in fibroblasts
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2.7M Array and following prescribed Affymetrix® proto-
cols. Chip analyses were carried out using Affymetrix
Chromosome Analysis Suite software (ChAS v.1.0.1) [23].
A Nimblegen array was also used in order to confirm the
data generated (Roche Nimblegen, Madison, WI, U.S.A.).
Genomic sequences were studied using the UCSC Genome
Browser database (UCSC GRCH37/hg19).
Real-time quantitative PCRs (RQ-PCR)
CNVs were validated by RQ-PCR via the ΔΔCT method,
using SYBR Green (Applied Biosystems, Life Technolo-
gies, Carlsbad, CA, USA) on an ABI 7500 real time PCR
system. RQ-PCRs for the proband, his parents, his
healthy brother, and several Lebanese reference samples
were run in triplicate. Primers were designed using Primer
Express 3 (ABI) for the quantification of PTPRD. α-
Actinin2 (ACTN2) and adenosine receptor 2b (ADORA2B)
were considered as endogenous genes. To exclude the
presence of unspecific products, a melting-curve analysis
of the products was performed after completion of the
amplification.
BAC DNA preparation and Fluorescence in situ
hybridization (FISH)
Fluorescence in situ hybridization was carried out to
confirm the presence of the undeleted intron 9 of
PTPRD (NM_002839), as detected by the Cyto2.7M
array. FISH was performed on fixed metaphase chromo-
somes obtained from the patient's peripheral blood cul-
ture. BAC clone DNA (CTD-2154L8) (provided by Life
technology, France), selected using UCSC genome browser
to be in intron 9 of PTPRD, was labeled with spectrum
Green-dUTP, using a nick translation kit (Abbott
Diagnostic, Rungis, France) according to the instruc-
tions of the manufacturers. A centromeric probe on
chromosome 9 was labeled with spectrum Orange-dUTP.
Hybridization was performed using standard procedures.
Chromosomes were counterstained with 4,6-diamino-2-
phenylindole (DAPI). Digital images were taken using an
Axioplan-2 Zeiss fluorescent microscope (Zeiss) and a
CCD camera (Photometrics « SenSys »).
Reverse transcription (RT-PCR)
The expression profile of PTPRD was studied by Reverse
Transcription on two panels of total RNAs (BD Biosci-
ences, Palo Alto, California, USA): 13 extracted from
human tissues and 12 from human brain areas. Com-
plementary DNAs (cDNA)s were synthesized using the
SuperScript II Reverse Transcriptase (Invitrogen Life
Technologies, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Primers were picked to high-
light the presence of the different length transcripts of
PTPRD obtained from UCSC Genomic Browser and
designed through the Primer3 software.
RNA isolation and cDNA synthesis
The patient's fibroblast cell lines were grown and main-
tained in DMEM media under standard tissue culture.
Total RNA was extracted from the patient’s cells using
Fig. 5 Graphical mapping of molecularly 9p24 interstitial deletions diagnosed in previously reported patients with trigonocephaly (blue bars) and
in the patient here described (red bar)
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the PerfectPure™ RNA Purification System - 5 PRIME,
and then transformed into cDNA as described above.
cDNAs of the patient and of a reference were amplified,
using random primers from Eurofins MWG Operon,
Germany, following these reaction cycling conditions:
94 °C for 2 min, 35 cycles of 94 °C for 30 sec, 60 °C for
30 sec, and 72 °C for 45 sec, with a post-cycling final
extension of 8 min at 72 °C.
Real-time quantitative PCR on cDNA extracted from
fibroblasts
The expression of IL1RAPL1, a protein that directly in-
teracts with the Immunoglobuline like (Ig-like) domains
of PTPRD, was studied. Specific primers were designed
through the Primer Express 3.0.1 software as follows:
IL1RAPL1-Forward: 5'-GCCAACCAGAGAACCTGAAAT
C-3' and IL1RAPL1-Reverse: 3'-CTTGGCCTCCATGTTT
TTGTC-5', PTPRD-Forward: 5'-AAGGGAATTCAAGGT
CACAGATG-3' and PTPRD-Reverse: 3' CAGTGAACTG
GAACTGCCTTACTG-5'. The reaction cycling conditions
were 95 °C for 10 min, followed by 40 cycles of: 95 °C for
15 sec and at 60 °C for 1 minute. Sequence Detection Soft-
ware (SDS) was used for exporting and analyzing differ-
ences in Ct values (ΔCt) between the test locus and the
control locus. c-abl oncogene 1, receptor tyrosine kinase
ABL1 was used as an endogene.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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